News
Abortion information largely ‘buried’ on most US hospital websites
The findings bring evidence to recent claims that hospitals have treated abortion care differently from other essential procedures
Despite being a routine procedure at many hospitals, abortion is not mentioned by almost 80 per cent of health system websites, a new study has found.
The report, published in Annals of Internal Medicine, has revealed that a lack of disclosure may contribute to stigma around abortion procedures in the US.
Patients often rely on online resources to learn about medications and procedures, including abortion. Online searches for abortion services are becoming more common after the Dobbs Supreme Court decision.
Patient-oriented webpages could play an important role in patients locating abortion providers, learning about the procedure, and scheduling care. However, it is unknown whether hospitals and their health systems offer these online resources.
Researchers from University of Pennsylvania Perelman School of Medicine and Harvard Medical School studied websites of 222 US hospitals in states without extreme abortion bans, including those with specialised abortion training programmes, to measure how often they offer information about abortion and its provision at their facilities compared with colonoscopy, another common procedure performed in both outpatient offices and hospitals.
The team found that 79.4 per cent of patient-facing websites did not mention abortion, compared with 11.1 per cent for colonoscopy.
When the websites did mention abortion services, the information was found a mean of 0.5 pages lower in search engine results.
The authors also reported that for websites offering information about abortion, 89.8 per cent omitted patient instructions for pre- or postprocedural care, compared with 42.2 per cent of websites offering information about colonoscopy.
According to the authors, their findings bring evidence to recent claims that hospitals have treated abortion care differently from other essential procedures, contributing to stigma surrounding abortion.
They said: “In summary, our results suggest that hospitals and their health systems are not advertising abortion in a manner consistent with other outpatient procedures nor consistent with medical society statements that abortion is routine, essential health care.”
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Menopause3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur5 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Wellness4 weeks agoVerdane invest in Clue to accelerate the future of women’s health







15 Comments